Original Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Jul 7, 2010; 16(25): 3133-3143
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Table 3 Efficacy in the ITT population
CharacteristicFOLFOX6 plus cetuximab (arm A, n = 77)FOLFIRI plus cetuximab (arm B, n = 74)
PFS
Events, n (%) 61 (79) 59 (80)
Median1, mo (95% CI)8.6 (6.3-9.7) 8.3 (7.4-8.7)
Log rank P-value0.7375
Hazard ratio (95% CI)1.06 (0.74-1.52)
PFS rate1, % (95% CI)
3 mo 92 (85-98)78 (68-88)
6 mo 69 (58-80)69 (58-80)
9 mo 45 (33-58)34 (23-46)
12 mo 18 (8-27) 18 (8-27)
Overall survival
Events, n (%) 54 (70) 50 (68)
Median1, mo (95% CI)17.4 (14.9-22.6)18.9 (14.7-23.9)
Logrank P-value0.9230
Hazard ratio2 (95% CI)0.98 (0.67-1.44)
Survival rate1, % (95% CI)
9 mo 79 (70-88)79 (70-89)
12 mo 70 (60-80)71 (60-81)
18 mo 46 (35-57)53 (42-65)
24 mo 33 (22-44)38 (26-50)
Best overall response, n (%)
CR  2 (3)  6 (8)
PR 31 (40) 27 (36)
SD 31 (40) 24 (32)
PD  6 (8) 9 (12)
NE  7 (9)  8 (11)
Objective response rate, n (%) 33 (43) 33 (45)
95% CI32-5533-57
Odds ratio (95% CI)0.93 (0.49-1.77)

  • Citation: Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143
  • URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3133